SVB Leerink Adjusts Blueprint Medicines' Price Target to $127 From $121

 Maintains Outperform

https://www.marketscreener.com/quote/stock/BLUEPRINT-MEDICINES-CORPO-22033569/news/Blueprint-Medicines-SVB-Leerink-Adjusts-Blueprint-Medicines-Price-Target-to-127-From-121-Keeps-32177477/

Credit Suisse Adjusts Thermo Fisher Scientific's Price Target to $580 from $556

 Maintains Outperform

https://www.marketscreener.com/quote/stock/THERMO-FISHER-SCIENTIFIC-14623/news/Thermo-Fisher-Scientific-Credit-Suisse-Adjusts-Thermo-Fisher-Scientific-s-Price-Target-to-580-fro-32177496/

Citigroup Downgrades Sarepta Therapeutics to Neutral from Buy

 Target $108

https://www.marketscreener.com/quote/stock/SAREPTA-THERAPEUTICS-INC-11204214/news/Sarepta-Therapeutics-Citigroup-Downgrades-Sarepta-Therapeutics-to-Neutral-from-Buy-Sets-108-Pric-32178716/

Oppenheimer Adjusts Price Target for Exact Sciences to $161 From $153

 Maintains Outperform

https://www.marketscreener.com/quote/stock/EXACT-SCIENCES-CORPORATIO-9232/news/Exact-Sciences-Oppenheimer-Adjusts-Price-Target-for-Exact-Sciences-to-161-From-153-Maintains-Ou-32179023/

Oppenheimer Adjusts Price Target for Invitae to $51 From $48

 Maintains Outperform

https://www.marketscreener.com/quote/stock/INVITAE-CORPORATION-23400709/news/Invitae-Oppenheimer-Adjusts-Price-Target-for-Invitae-to-51-From-48-Maintains-Outperform-Rating-32179077/

SVB Leerink Adjusts Karyopharm Therapeutics' Price Target to $25 from $29

 Keeps Outperform rating

https://www.marketscreener.com/quote/stock/KARYOPHARM-THERAPEUTICS-I-14825950/news/Karyopharm-Therapeutics-SVB-Leerink-Adjusts-Karyopharm-Therapeutics-Price-Target-to-25-from-29-32179238/

Oppenheimer Adjusts Price Target for Turning Point Therapeutics to $150 From $130

 Maintains Outperform rating

https://www.marketscreener.com/quote/stock/TURNING-POINT-THERAPEUTIC-57237713/news/Turning-Point-Therapeutics-Oppenheimer-Adjusts-Price-Target-for-Turning-Point-Therapeutics-to-150-32179186/